Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Enabling a new era in minimally invasive obesity treatment across Europe
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
Maria Soler Nunez appointed as Chief Quality Officer
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
Subscribe To Our Newsletter & Stay Updated